Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
metabolic health
Advertisement
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
Phase II Data Support MCS-8 Potential in Cancer Prevention
NEW TAIPEI CITY, Taiwan, Jan. 30, 2026 — Jyong Biotech announced updated Phase II clinical trial results for its...
Jupiter Expands Nugevia™ Strategy for GLP-1 Users
Jupiter, Florida | January 28, 2026 — Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, announced a strategic expansion of...
Advertisement
